Bill & Melinda Gates Foundation-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Bill & Melinda Gates Foundation - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011882
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bill & Melinda Gates Foundation (BMGF), formerly William H. Gates Foundation is a provider of health development programs. The foundation concentrates on improving healthcare, decrease poverty in America and provides access to information equipment. It offers global health services in the fields of discovery and translational sciences, enteric and diarrheal diseases, HIV, malaria, neglected infectious diseases, and tuberculosis services. BMGF’s global development services include agricultural development, family planning, emergency response, financial services for the poor, nutrition fulfillment, vaccine delivery, and water, sanitation and hygiene services. The foundation has its presence in Asia, Africa, Europe, North America, South America, and Oceania. BMGF is headquartered in Seattle, Washington, the US.

Bill & Melinda Gates Foundation – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Bill & Melinda Gates Foundation, Medical Devices Deals, 2011 to YTD 2017 10
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Visterra Raises Additional USD23.6 Million in Series C Financing 13
Arsanis Raises USD45.5 Million in Series D Financing 15
Kymab Raises USD100.5 Million in Series C Financing 17
Just Biotherapeutics Raises USD14 Million in Series A2 Financing 19
Affinivax Raises USD2.5 Million in Venture Financing 21
Lodo Therapeutics Raises USD17 Million in Series A Financing 22
Atreca Raises USD56 Million in Series A Financing 24
CureVac to Raise USD76 Million in Venture Financing 25
Affinivax Raises USD4 Million in Seed Venture Financing 26
Synlogic Raises Additional USD5 Million in Series A Venture Financing 27
Kymab Raises USD40 Million in Series B Financing 28
Visterra Raises US$8.1 Million In Extended Series A Financing 29
Visterra Raises Additional US$13 Million In Series A Financing 31
Genocea Biosciences Raises US$30 Million In Series C Financing 33
Partnerships 35
CureVac to Enter into Development Agreement with Bill & Melinda Gates 35
Sanofi Pasteur Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 36
GSK Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 37
Anacor Pharma Ammends its Research Agreement With Bill & Melinda Gates Foundation 38
Atreca Enters into Agreement with Bill & Melinda Gates Foundation 39
Equity Offering 40
Intarcia Therapeutics Raises USD206 Million in Second Tranche of Private Placement of Shares 40
CureVac Raises USD110 Million in Private Placement of Shares 41
Bill & Melinda Gates Foundation – Key Competitors 42
Bill & Melinda Gates Foundation – Key Employees 43
Bill & Melinda Gates Foundation – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 44
Recent Developments 45
Government and Public Interest 45
Nov 29, 2017: Phyton Biotech Wins Grant to Develop New Approaches to Manufacturing Artemisinin 45
Oct 23, 2017: Ventria Bioscience aids global fight against intestinal infections that threaten up to 400 million children a year 46
Aug 18, 2017: IHI Partners with South Africa National Department of Health on Initiative to Improve Tuberculosis Care and Outcomes 47
Jun 12, 2017: Rotary and the Bill & Melinda Gates Foundation announce $450 million commitment to end polio 48
Mar 06, 2017: Vaxess Technologies Receives Grants Totaling $6 Million to Develop Microneedle Vaccines for Polio, Measles, Rubella 49
Jan 09, 2017: Kymab expands Infectious Disease Programmes 50
Dec 02, 2016: Access Bio recieved a USD $3.7 million grant from the Bill & Melinda Gates Foundation 51
Oct 19, 2016: Pfizer Awarded Grant to Evaluate Vaccine to Protect Newborns Against Group B Streptococcus Infection 52
Oct 18, 2016: Gates Foundation Awards $1.1 Million Grant for MediBeacon Collaboration with Washington University 53
Jun 09, 2016: Batavia Biosciences Receives Grant from the Bill & Melinda Gates Foundation to Support Vaccine Availability in Developing Count 54
May 26, 2016: EnBiotix, Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 55
Jan 18, 2016: Evestra Receives Gates Foundation Grant 56
Jan 12, 2016: Moderna Therapeutics, Through Valera, its Infectious Disease Venture, Announces Initial Grant of up to $20 Million to Advance mRNA-Based Antibody Combination to Help Prevent HIV Infection 57
Product News 58
Jul 20, 2016: Penn-led team develops plant-based Polio booster vaccine 58
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Key Facts 2
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Bill & Melinda Gates Foundation, Deals By Therapy Area, 2011 to YTD 2017 9
Bill & Melinda Gates Foundation, Medical Devices Deals, 2011 to YTD 2017 10
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Visterra Raises Additional USD23.6 Million in Series C Financing 13
Arsanis Raises USD45.5 Million in Series D Financing 15
Kymab Raises USD100.5 Million in Series C Financing 17
Just Biotherapeutics Raises USD14 Million in Series A2 Financing 19
Affinivax Raises USD2.5 Million in Venture Financing 21
Lodo Therapeutics Raises USD17 Million in Series A Financing 22
Atreca Raises USD56 Million in Series A Financing 24
CureVac to Raise USD76 Million in Venture Financing 25
Affinivax Raises USD4 Million in Seed Venture Financing 26
Synlogic Raises Additional USD5 Million in Series A Venture Financing 27
Kymab Raises USD40 Million in Series B Financing 28
Visterra Raises US$8.1 Million In Extended Series A Financing 29
Visterra Raises Additional US$13 Million In Series A Financing 31
Genocea Biosciences Raises US$30 Million In Series C Financing 33
CureVac to Enter into Development Agreement with Bill & Melinda Gates 35
Sanofi Pasteur Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 36
GSK Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 37
Anacor Pharma Ammends its Research Agreement With Bill & Melinda Gates Foundation 38
Atreca Enters into Agreement with Bill & Melinda Gates Foundation 39
Intarcia Therapeutics Raises USD206 Million in Second Tranche of Private Placement of Shares 40
CureVac Raises USD110 Million in Private Placement of Shares 41
Bill & Melinda Gates Foundation, Key Competitors 42
Bill & Melinda Gates Foundation, Key Employees 43
Bill & Melinda Gates Foundation, Other Locations 44
Bill & Melinda Gates Foundation, Joint Venture 44

★海外企業調査レポート[Bill & Melinda Gates Foundation-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Guangzhou R&F Properties Co Ltd:戦略・SWOT・企業財務分析
    Guangzhou R&F Properties Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Guangzhou R&F Properties Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Pacific Scientific Energetic Materials Company:企業の戦略・SWOT・財務情報
    Pacific Scientific Energetic Materials Company - Strategy, SWOT and Corporate Finance Report Summary Pacific Scientific Energetic Materials Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • BioInvent International AB (BINV):企業の財務・戦略的SWOT分析
    BioInvent International AB (BINV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Wellcome Trust Sanger Institute-医療機器分野:企業M&A・提携分析
    Summary Wellcome Trust Sanger Institute (Sanger Institute), a subsidiary of Genome Research Ltd is a genomic discovery and research centre that carries out research and development in the areas of cellular and human genetics and infection genomics. It also provides postgraduate training on research …
  • FUDAN University-製薬・医療分野:企業M&A・提携分析
    Summary FUDAN University (FUDAN) is an educational university that offers bachelor, undergraduate, master and doctoral degrees in various disciplines. The university confers bachelor's degrees in multiple academic disciplines. It conducts research in various disciplines such as natural sciences, dep …
  • Enlight Renewable Energy Ltd (ENLT):企業の財務・戦略的SWOT分析
    Summary Enlight Renewable Energy Ltd (Enlight Renewable) is a renewable energy company that invests, develops, finances, constructs, operates and manages electricity production projects from renewable energy sources. The company develops photovoltaic technology by which solar energy is converted to …
  • Chronix Biomedical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Chronix Biomedical Inc (Chronix Biomedical) is a molecular diagnostic company that develops blood tests for monitoring minimal residual disease in cancer patients. The company offers tests such as second opinion tests and delta dot tests. Its second opinion tests include supplementary blood …
  • Eckoh PLC (ECK):企業の財務・戦略的SWOT分析
    Summary Eckoh PLC (Eckoh) is a technology service provider that offers secure payment products and customer service solutions. The company provides agent assisted payments, IVR payments, mobile and web payments and GPDR. Its agent assisted payments include DTMF Masking, audio tokenization, alternati …
  • Venture Global LNG Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Venture Global LNG Inc (VGLI) is an exporter of american-produced liquefied natural gas. The company owns and manages two Louisiana-based export projects Calcasieu Pass and Plaquemines. The company through subsidiary Venture Global Calcasieu Pass, LLC, operates Calcasieu Pass project, which …
  • Lekoil Ltd (LEK):企業の財務・戦略的SWOT分析
    Summary Lekoil Ltd (Lekoil) is an oil and gas exploration and production company with interests in Nigeria and Namibia. The company owns oil and gas exploration and production properties such as Otakikpo marginal field, Nigeria Dahomey Basin OPL310 and Nigeria Dahomey Basin OPL 325 in Nigeria, and B …
  • American Greetings Corporation:企業の戦略・SWOT・財務情報
    American Greetings Corporation - Strategy, SWOT and Corporate Finance Report Summary American Greetings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Henry Schein Inc (HSIC)-医療機器分野:企業M&A・提携分析
    Summary Henry Schein, Inc. (Henry Schein) is a distributor of healthcare products and services. Its product and service portfolio consists of dental products, medical products, animal health products, software and technology and other value-added services. It offers generic and branded pharmaceutica …
  • Santee Cooper:企業の戦略的SWOT分析
    Santee Cooper - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • LifeVantage Corp (LFVN):企業の財務・戦略的SWOT分析
    Summary LifeVantage Corp (LifeVantage) is a science-based nutraceutical company that manufactures and markets dietary supplements. The company provides products such as protandim, axio, physiq, truescience and canine health, among others. Its beauty products include cleansers, hand creams, micro lif …
  • Avista Corporation:企業の戦略・SWOT・財務分析
    Avista Corporation - Strategy, SWOT and Corporate Finance Report Summary Avista Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Flint Hills Resources LLC:企業の戦略的SWOT分析
    Flint Hills Resources LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • j2 Global, Inc.:企業のM&A・事業提携・投資動向
    j2 Global, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's j2 Global, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • GAIN Capital Holdings, Inc.:企業のM&A・事業提携・投資動向
    GAIN Capital Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's GAIN Capital Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Dah Chong Hong Holdings Ltd (1828):企業の財務・戦略的SWOT分析
    Dah Chong Hong Holdings Ltd (1828) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Matador Resources Co (MTDR):企業の財務・戦略的SWOT分析
    Summary Matador Resources Co (Matador Resources) is an energy company that explores, develops, and produces crude oil and natural gas resources. It offers new oil and natural gas prospects for exploring and developing hydrocarbons in the US basins. In addition, the company carries out exploration, p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆